Skip to main content
SpringerLink
Log in

Therapeutically Used Targeted Antigens in Radioimmunotherapy

  • Chapter
Targeted Radionuclide Tumor Therapy

Summary

Many antigens have been tested as targets for radioimmunotherapy with intact antibodies. Some of the early used targets have been found to be of decreasing interest due to low expression, extensive shedding or other reasons. Others have been found more useful due to their accessibility, amount available in the tumours, or the biological properties of the target antigen. In this chapter some of the most used antigens and their characteristics are presented.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Voorzanger-Rousselot N, Garnero P: Biochemical markers in oncology. Part I: Molecular basis. Part II: Clinical uses. Cancer Treat Rev 2007; 33:230-283.

    Article  PubMed  CAS  Google Scholar 

  2. Gold P, Freedman SO: Specific carcinoembryonic antigens of the human digestive system. J Exp Med 1965; 122:467-481.

    Article  PubMed  CAS  Google Scholar 

  3. Mach JP, Carrel S, Merenda C, Sordat B, Cerottini JC: In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice. Nature 1974; 248:704-706.

    Article  PubMed  CAS  Google Scholar 

  4. Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, van Nagell JR, Jr., Estes N, DeSimone P, Rayburn P: Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978; 298:1384-1386.

    Article  PubMed  CAS  Google Scholar 

  5. Hammarstrom S: The carcinoembryonic antigen (cea) family: Structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999; 9:67-81.

    Article  PubMed  CAS  Google Scholar 

  6. Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, Hansen HJ, Horak ID, Goldenberg DM: Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005; 11:1250-1255.

    Article  PubMed  CAS  Google Scholar 

  7. Jia F, Shelton TD, Lewis MR: Preparation, characterization, and biological evaluation of a streptavidin-chimeric t84.66 conjugate for antibody pretargeting. Cancer Biother Radiopharm 2007; 22:654-664.

    Article  PubMed  CAS  Google Scholar 

  8. Wong JY, Chu DZ, Williams LE, Liu A, Zhan J, Yamauchi DM, Wilczynski S, Wu AM, Yazaki PJ, Shively JE, Leong L, Raubitschek AA: A phase I trial of (90)y-dota-anti-cea chimeric t84.66 (ct84.66) radioimmunotherapy in patients with metastatic cea-producing malignancies. Cancer Biother Radiopharm 2006; 21:88-100.

    Article  PubMed  CAS  Google Scholar 

  9. Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH: Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med 2008; 49:158-163.

    Article  PubMed  CAS  Google Scholar 

  10. Sharkey RM, Karacay H, Vallabhajosula S, McBride WJ, Rossi EA, Chang CH, Goldsmith SJ, Goldenberg DM: Metastatic human colonic carcinoma: Molecular imaging with pretargeted spect and pet in a mouse model. Radiology 2008; 246:497-507.

    Article  PubMed  Google Scholar 

  11. Kraeber-Bodere F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J: Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131i-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med 2006; 47:247-255.

    PubMed  CAS  Google Scholar 

  12. Lankester KJ, Maxwell RJ, Pedley RB, Dearling JL, Qureshi UA, El-Emir E, Hill SA, Tozer GM: Combretastatin a-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131i-a5b7, even at doses that are sub-optimal for vascular shut-down. Int J Oncol 2007; 30:453-460.

    PubMed  CAS  Google Scholar 

  13. Chatal JF, Campion L, Kraeber-Bodere F, Bardet S, Vuillez JP, Charbonnel B, Rohmer V, Chang CH, Sharkey RM, Goldenberg DM, Barbet J: Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: A collaborative study with the french endocrine tumor group. J Clin Oncol 2006; 24:1705-1711.

    Article  PubMed  CAS  Google Scholar 

  14. Karacay H, Brard PY, Sharkey RM, Chang CH, Rossi EA, McBride WJ, Ragland DR, Horak ID, Goldenberg DM: Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res 2005; 11:7879-7885.

    Article  PubMed  CAS  Google Scholar 

  15. Li GP, Zhang H, Zhu CM, Zhang J, Jiang XF: Avidin-biotin system pretargeting radioimmunoimaging and radioimmunotherapy and its application in mouse model of human colon carcinoma. World J Gastroenterol 2005; 11:6288-6294.

    PubMed  CAS  Google Scholar 

  16. Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D: Analysis of a human tumor-associated glycoprotein (tag-72) identified by monoclonal antibody b72.3. Cancer Res 1986; 46:850-857.

    PubMed  CAS  Google Scholar 

  17. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J: Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody b72.3. Cancer Res 1986; 46:3118-3124.

    PubMed  CAS  Google Scholar 

  18. Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D: Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 2002; 13:603-608.

    Article  PubMed  CAS  Google Scholar 

  19. Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, Schlom J, Russell CD, Liu T, LoBuglio AF: Treatment of metastatic prostate carcinoma with radiolabeled antibody cc49. J Nucl Med 1994; 35:1017-1022.

    PubMed  CAS  Google Scholar 

  20. Divgi CR, Scott AM, Dantis L, Capitelli P, Siler K, Hilton S, Finn RD, Kemeny N, Kelsen D, Kostakoglu L, et al.: Phase I radioimmunotherapy trial with iodine-131-cc49 in metastatic colon carcinoma. J Nucl Med 1995; 36:586-592.

    PubMed  CAS  Google Scholar 

  21. Meredith RF, Khazaeli MB, Liu T, Plott G, Wheeler RH, Russell C, Colcher D, Schlom J, Shochat D, LoBuglio AF: Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 1992; 33:1648-1653.

    PubMed  CAS  Google Scholar 

  22. Meredith RF, Khazaeli MB, Plott WE, Grizzle WE, Liu T, Schlom J, Russell CD, Wheeler RH, LoBuglio AF: Phase II study of dual 131i-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res 1996; 2:1811-1818.

    PubMed  CAS  Google Scholar 

  23. Murray JL, Macey DJ, Kasi LP, Rieger P, Cunningham J, Bhadkamkar V, Zhang HZ, Schlom J, Rosenblum MG, Podoloff DA: Phase II radioimmunotherapy trial with 131i-cc49 in colorectal cancer. Cancer 1994; 73:1057-1066.

    Article  PubMed  CAS  Google Scholar 

  24. Ponnusamy MP, Venkatraman G, Singh AP, Chauhan SC, Johansson SL, Jain M, Smith L, Davis JS, Remmenga SW, Batra SK: Expression of tag-72 in ovarian cancer and its correlation with tumor stage and patient prognosis. Cancer Lett 2007; 251:247-257.

    Article  PubMed  CAS  Google Scholar 

  25. Chauhan SC, Jain M, Moore ED, Wittel UA, Li J, Gwilt PR, Colcher D, Batra SK: Pharmacokinetics and biodistribution of 177lu-labeled multivalent single-chain fv construct of the pancarcinoma monoclonal antibody cc49. Eur J Nucl Med Mol Imaging 2005; 32:264-273.

    Article  PubMed  CAS  Google Scholar 

  26. Goel A, Colcher D, Baranowska-Kortylewicz J, Augustine S, Booth BJ, Pavlinkova G, Batra SK: Genetically engineered tetravalent single-chain fv of the pancarcinoma monoclonal antibody cc49: Improved biodistribution and potential for therapeutic application. Cancer Res 2000; 60:6964-6971.

    PubMed  CAS  Google Scholar 

  27. Kashmiri SV, Shu L, Padlan EA, Milenic DE, Schlom J, Hand PH: Generation, characterization, and in vivo studies of humanized anticarcinoma antibody cc49. Hybridoma 1995; 14:461-473.

    Article  PubMed  CAS  Google Scholar 

  28. Larson SM, El-Shirbiny AM, Divgi CR, Sgouros G, Finn RD, Tschmelitsch J, Picon A, Whitlow M, Schlom J, Zhang J, Cohen AM: Single chain antigen binding protein (sfv cc49): First human studies in colorectal carcinoma metastatic to liver. Cancer 1997; 80:2458-2468.

    Article  PubMed  CAS  Google Scholar 

  29. Chauhan SC, Vinayek N, Maher DM, Bell MC, Dunham KA, Koch MD, Lio Y, Jaggi M: Combined staining of tag-72, muc1, and ca125 improves labeling sensitivity in ovarian cancer: Antigens for multi-targeted antibody-guided therapy. J Histochem Cytochem 2007; 55:867-875.

    Article  PubMed  CAS  Google Scholar 

  30. Langton BC, Crenshaw MC, Chao LA, Stuart SG, Akita RW, Jackson JE: An antigen immunologically related to the external domain of gp185 is shed from nude mouse tumors overexpressing the c-erbb-2 (her-2/neu) oncogene. Cancer Res 1991; 51:2593-2598.

    PubMed  CAS  Google Scholar 

  31. Han H, Landreneau RJ, Santucci TS, Tung MY, Macherey RS, Shackney SE, Sturgis CD, Raab SS, Silverman JF: Prognostic value of immunohistochemical expressions of p53, her-2/ neu, and bcl-2 in stage I non-small-cell lung cancer. Hum Pathol 2002; 33:105-110.

    Article  PubMed  CAS  Google Scholar 

  32. Ross JS, Fletcher JA: The her-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Oncologist 1998; 3:237-252.

    PubMed  Google Scholar 

  33. Calvo BF, Levine AM, Marcos M, Collins QF, Iacocca MV, Caskey LS, Gregory CW, Lin Y, Whang YE, Earp HS, Mohler JL: Human epidermal receptor-2 expression in prostate cancer. Clin Cancer Res 2003; 9:1087-1097.

    PubMed  CAS  Google Scholar 

  34. Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Norgaard-Pedersen B, Hogdall CK: Distribution of her-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: From the Danish malova ovarian cancer study. Cancer 2003; 98:66-73.

    Article  PubMed  CAS  Google Scholar 

  35. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19:183-232.

    Article  PubMed  CAS  Google Scholar 

  36. Carlsson J, Ren ZP, Wester K, Sundberg AL, Heldin NE, Hesselager G, Persson M, Gedda L, Tolmachev V, Lundqvist H, Blomquist E, Nister M: Planning for intracavitary anti-egfr radionuclide therapy of gliomas. Literature review and data on egfr expression. J Neurooncol 2006; 77:33-45.

    Article  PubMed  CAS  Google Scholar 

  37. Ohman L, Gedda L, Hesselager G, Larsson R, Nister M, Stigbrand T, Wester K, Carlsson J: A new antibody recognizing the viii mutation of human epidermal growth factor receptor. Tumour Biol 2002; 23:61-69.

    Article  PubMed  Google Scholar 

  38. Ritter G, Cohen LS, Nice EC, Catimel B, Burgess AW, Moritz RL, Ji H, Heath JK, White SJ, Welt S, Old LJ, Simpson RJ: Characterization of posttranslational modifications of human a33 antigen, a novel palmitoylated surface glycoprotein of human gastrointestinal epithelium. Biochem Biophys Res Commun 1997; 236:682-686.

    Article  PubMed  CAS  Google Scholar 

  39. Heath JK, White SJ, Johnstone CN, Catimel B, Simpson RJ, Moritz RL, Tu GF, Ji H, Whitehead RH, Groenen LC, Scott AM, Ritter G, Cohen L, Welt S, Old LJ, Nice EC, Burgess AW: The human a33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. Proc Natl Acad Sci USA 1997; 94:469-474.

    Article  PubMed  CAS  Google Scholar 

  40. Almqvist Y, Steffen AC, Tolmachev V, Divgi CR, Sundin A: In vitro and in vivo characterization of 177lu-hua33: A radioimmunoconjugate against colorectal cancer. Nucl Med Biol 2006; 33:991-998.

    Article  PubMed  CAS  Google Scholar 

  41. Sakamoto J, Oriuchi N, Mochiki E, Asao T, Scott AM, Hoffman EW, Jungbluth AA, Matsui T, Lee FT, Papenfuss A, Kuwano H, Takahashi T, Endo K, Old LJ: A phase I radioimmunolocalization trial of humanized monoclonal antibody hua33 in patients with gastric carcinoma. Cancer Sci 2006; 97:1248-1254.

    Article  PubMed  CAS  Google Scholar 

  42. Chong G, Lee FT, Hopkins W, Tebbutt N, Cebon JS, Mountain AJ, Chappell B, Papenfuss A, Schleyer P, Paul U, Murphy R, Wirth V, Smyth FE, Potasz N, Poon A, Davis ID, Saunder T, O’Keefe GJ, Burgess AW, Hoffman EW, Old LJ, Scott AM: Phase I trial of 131i-hua33 in patients with advanced colorectal carcinoma. Clin Cancer Res 2005; 11:4818-4826.

    Article  PubMed  CAS  Google Scholar 

  43. Singh R, Bandyopadhyay D: Muc1: A target molecule for cancer therapy. Cancer Biol Ther 2007; 6:481-486.

    Article  PubMed  CAS  Google Scholar 

  44. Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, Haga S, Kiyozuka Y, Schol D, Meulenbroek MF, Snijdewint FG, von Mensdorff-Pouilly S, Verstraeten RA, Kenemans P, Blockzjil A, Nilsson K, Nilsson O, Reddish M, Suresh MR, Koganty RR, Fortier S, Baronic L, Berg A, Longenecker MB, Hilgers J, et al.: Summary report on the isobm td-4 workshop: Analysis of 56 monoclonal antibodies against the muc1 mucin. San Diego, California, November 17-23, 1996. Tumour Biol 1998; 19(Suppl 1):1-20.

    Article  PubMed  Google Scholar 

  45. Nicholson S, Gooden CS, Hird V, Maraveyas A, Mason P, Lambert HE, Meares CF, Epenetos AA: Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: A matched analysis. Oncol Rep 1998; 5:223-226.

    PubMed  CAS  Google Scholar 

  46. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219:983-985.

    Article  PubMed  CAS  Google Scholar 

  47. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-1309.

    Article  PubMed  CAS  Google Scholar 

  48. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991; 266:11947-11954.

    PubMed  CAS  Google Scholar 

  49. Kuroi K, Toi M: Circulating angiogenesis regulators in cancer patients. Int J Biol Markers 2001; 16:5-26.

    PubMed  CAS  Google Scholar 

  50. Crew JP, O’Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D, Harris AL: Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 1997; 57:5281-5285.

    PubMed  CAS  Google Scholar 

  51. Vaquero J, Zurita M, Morales C, Cincu R, Oya S: Expression of vascular permeability factor in glioblastoma specimens: Correlation with tumor vascular endothelial surface and peritumoral edema. J Neurooncol 2000; 49:49-55.

    Article  PubMed  CAS  Google Scholar 

  52. Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R: P53 and vascular-endothelialgrowth-factor (vegf) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer 2000; 89:51-62.

    Article  PubMed  CAS  Google Scholar 

  53. Tokunaga T, Oshika Y, Abe Y, Ozeki Y, Sadahiro S, Kijima H, Tsuchida T, Yamazaki H, Ueyama Y, Tamaoki N, Nakamura M: Vascular endothelial growth factor (vegf) mrna isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 1998; 77:998-1002.

    PubMed  CAS  Google Scholar 

  54. Fontanini G, Faviana P, Lucchi M, Boldrini L, Mussi A, Camacci T, Mariani MA, Angeletti CA, Basolo F, Pingitore R: A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 2002; 86:558-563.

    Article  PubMed  CAS  Google Scholar 

  55. Fujimoto J, Sakaguchi H, Aoki I, Khatun S, Tamaya T: Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian cancers. Br J Cancer 2001; 85:313-316.

    Article  PubMed  CAS  Google Scholar 

  56. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B: Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000; 163:343-347.

    Article  PubMed  CAS  Google Scholar 

  57. Sauter ER, Nesbit M, Watson JC, Klein-Szanto A, Litwin S, Herlyn M: Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck. Clin Cancer Res 1999; 5:775-782.

    PubMed  CAS  Google Scholar 

  58. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP: High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 2000; 6:1900-1908.

    PubMed  CAS  Google Scholar 

  59. Chen J, Wu H, Han D, Xie C: Using anti-vegf mcab and magnetic nanoparticles as doubletargeting vector for the radioimmunotherapy of liver cancer. Cancer Lett 2006; 231:169-175.

    Article  PubMed  CAS  Google Scholar 

  60. Nadler LM, Ritz J, Hardy R, Pesando JM, Schlossman SF, Stashenko P: A unique cell surface antigen identifying lymphoid malignancies of b cell origin. J Clin Invest 1981; 67:134-140.

    Article  PubMed  CAS  Google Scholar 

  61. Manshouri T, Do KA, Wang X, Giles FJ, O’Brien SM, Saffer H, Thomas D, Jilani I, Kantarjian HM, Keating MJ, Albitar M: Circulating cd20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood 2003; 101:2507-2513.

    Article  PubMed  CAS  Google Scholar 

  62. Keating M, O’Brien S: High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol 2000; 27:86-90.

    PubMed  CAS  Google Scholar 

  63. Emmanouilides C: Radioimmunotherapy for non-hodgkin lymphoma: Historical perspective and current status. J Clin Exp Hematop 2007; 47:43-60.

    Article  PubMed  Google Scholar 

  64. Emmanouilides C: Current treatment options in follicular lymphoma: Science and bias. Leuk Lymphoma 2007:1-12.

    Google Scholar 

  65. Green DJ, Pagel JM, Pantelias A, Hedin N, Lin Y, Wilbur DS, Gopal A, Hamlin DK, Press OW: Pretargeted radioimmunotherapy for b-cell lymphomas. Clin Cancer Res 2007; 13:5598s-5603s.

    Article  PubMed  CAS  Google Scholar 

  66. Pagel JM, Hedin N, Subbiah K, Meyer D, Mallet R, Axworthy D, Theodore LJ, Wilbur DS, Matthews DC, Press OW: Comparison of anti-cd20 and anti-cd45 antibodies for conventional and pretargeted radioimmunotherapy of b-cell lymphomas. Blood 2003; 101:2340-2348.

    Article  PubMed  CAS  Google Scholar 

  67. Witzig TE: Radioimmunotherapy for b-cell non-hodgkin lymphoma. Best Pract Res Clin Haematol 2006; 19:655-668.

    Article  PubMed  CAS  Google Scholar 

  68. Johansson A, Sandstrom P, Ullen A, Behravan G, Erlandsson A, Levi M, Sundstrom B, Stigbrand T: Epitope specificity of the monoclonal anticytokeratin antibody ts1. Cancer Res 1999; 59:48-51.

    PubMed  CAS  Google Scholar 

  69. Ullen A, Sandstrom P, Ahlstrom KR, Sundstrom B, Nilsson B, Arlestig L, Stigbrand T: Use of anticytokeratin monoclonal antiidiotypic antibodies to improve tumor/nontumor ratio in experimental radioimmunolocalization. Cancer Res 1995; 55:S5868-S5873.

    Google Scholar 

  70. Eriksson D, Joniani HM, Sheikholvaezin A, Lofroth PO, Johansson L, Ahlstrom KR, Stigbrand T: Combined low dose radio- and radioimmunotherapy of experimental hela hep 2 tumours. Eur J Nucl Med Mol Imaging 2003; 30:895-906.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, University of Umeå, SE-90185, Umeå, Sweden

    Torgny Stigbrand & David Eriksson

  2. Departments of Clinical Microbiology, Diagnostic Radiology, University of Umeå, SE-90185, Umeå, Sweden

    Katrine Riklund

  3. Department of Radiation Physics, University of Umeå, SE-90185, Umeå, Sweden

    Lennart Johansson

Authors
  1. Torgny Stigbrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Eriksson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katrine Riklund
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lennart Johansson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Immunology, University of Umea, Umea, Sweden

    Torgny Stigbrand

  2. Rudbeck Laboratory, Uppsala University, Uppsala, Sweden

    Jörgen Carlsson

  3. Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA

    Gregory P. Adams

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science + Business Media B.V

About this chapter

Cite this chapter

Stigbrand, T., Eriksson, D., Riklund, K., Johansson, L. (2008). Therapeutically Used Targeted Antigens in Radioimmunotherapy. In: Stigbrand, T., Carlsson, J., Adams, G.P. (eds) Targeted Radionuclide Tumor Therapy. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-8696-0_2

Download citation

Publish with us

Policies and ethics

Search

Navigation